newsfilter
← Latest News
GlobeNewswire·

Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results

Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9 Mean reduction in LDL-C of 53%, with a maximum reduction of 69%,